Compare ATLO & HELP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ATLO | HELP |
|---|---|---|
| Founded | 1903 | N/A |
| Country | United States | Canada |
| Employees | N/A | 50 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 239.2M | 281.4M |
| IPO Year | 2001 | N/A |
| Metric | ATLO | HELP |
|---|---|---|
| Price | $27.70 | $4.50 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $95.00 |
| AVG Volume (30 Days) | 34.7K | ★ 1.1M |
| Earning Date | 04-16-2026 | 07-01-2026 |
| Dividend Yield | ★ 3.00% | N/A |
| EPS Growth | ★ 8.03 | N/A |
| EPS | ★ 0.38 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $70.66 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.09 | $4.52 |
| 52 Week High | $28.35 | $8.55 |
| Indicator | ATLO | HELP |
|---|---|---|
| Relative Strength Index (RSI) | 59.71 | 33.77 |
| Support Level | $25.95 | N/A |
| Resistance Level | $28.07 | $7.28 |
| Average True Range (ATR) | 0.71 | 0.44 |
| MACD | 0.00 | -0.11 |
| Stochastic Oscillator | 89.50 | 3.35 |
Ames National Corporation is a bank holding company based in the United States. Through its subsidiaries, it provides a range of banking and other financial products and services to customers in Iowa, mainly in Boone, Clarke, Hancock, Marshall, Polk, Story, Taylor, and Union in central, north-central, and south-central Iowa. The Group offers several financial products and services, including checking and savings accounts, time deposits, commercial, construction, and agricultural loans, personal loans, lines of credit, cash management services, merchant credit card processing, safe deposit boxes, and ATM services, among others. It caters to the banking needs of a diverse range of customers, including individuals, businesses, professionals, and enterprises.
Helus Pharma Inc is a clinical-stage pharmaceutical company developing proprietary novel serotonergic agonists (NSAs), which are synthetic molecules designed to activate serotonin pathways associated with neuroplasticity. These compounds are being investigated for potential use in the treatment of depression, anxiety, and other mental health conditions, areas where there is an unmet medical need. It aims to provide treatments designed for mental health disorders. The company is currently developing HLP003, a proprietary NSA, in Phase 3 clinical development for the adjunctive treatment of substantial depressive disorder. It operates in Canada, the United States, the United Kingdom, and Ireland.